secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cytek Biosciences, Inc. (CTKB)
CIK:        0001831915
Form:       8-K
Filed at:   2024-03-19T23:59:59+00:00
Accession:  0001193125-24-071467
Event type: leadership
Sentiment:  neutral
Materiality: 0.70
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cytek Biosciences appoints William McCombe as CFO, reaffirms 2024 revenue guidance
--------------------------------------------------------------------------------

- Patrik Jeanmonod steps down as CFO to become Head of Corporate Development Analytics, effective March 17, 2024.
- William McCombe appointed CFO effective March 18, 2024; base salary $420,000, target bonus 50%, equity grant $1.25M.
- McCombe previously CFO at Velo3D, HZO, and Maxar Technologies; over 20 years investment banking experience.
- Cytek reaffirms 2024 revenue guidance of $203M-$213M (5-10% growth) and expectation of positive net income.
- No disagreement cited for Jeanmonod's transition; company reiterates 2024 outlook unchanged.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831915/000119312524071467/0001193125-24-071467-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831915/000119312524071467/d773908d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-071467

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer